{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T08:28:13Z","timestamp":1782289693045,"version":"3.54.5"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jneuroim.2021.577761","type":"journal-article","created":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T23:01:09Z","timestamp":1635894069000},"page":"577761","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Clinical burden of relapses in aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder: A single center cohort analysis"],"prefix":"10.1016","volume":"362","author":[{"given":"Robert","family":"Kadish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey L.","family":"Clardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minying","family":"Royston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Tanvir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tavan","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Biskupiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Kielhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2021.577761_bb0005","doi-asserted-by":"crossref","first-page":"13890","DOI":"10.1038\/s41598-020-70919-w","article-title":"Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders","volume":"10","author":"Akaishi","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jneuroim.2021.577761_bb0010","article-title":"Pain in AQP4-IgG-positive and MOG-IgG-positive neuromyelitis optica spectrum disorders","volume":"4","author":"Asseyer","year":"2018","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"10.1016\/j.jneuroim.2021.577761_bb0015","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000580","article-title":"Neuromyelitis optica spectrum disorder: patient experience and quality of life","volume":"6","author":"Beekman","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2021.577761_bb0020","first-page":"741490","article-title":"Immunotherapy of neuromyelitis optica","volume":"2013","author":"Bienia","year":"2013","journal-title":"Autoimmune Dis."},{"key":"10.1016\/j.jneuroim.2021.577761_bb0025","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.4103\/0972-2327.164818","article-title":"Therapy of NMO spectrum disorders","volume":"18","author":"Biswas","year":"2015","journal-title":"Ann. Indian Acad. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577761_bb0030","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","article-title":"Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders","volume":"89","author":"Bonnan","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2021.577761_bb0035","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fneur.2018.00888","article-title":"Diagnosis and treatment of NMO Spectrum disorder and MOG-encephalomyelitis","volume":"9","author":"Borisow","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577761_bb0040","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/WNO.0000000000000403","article-title":"Neuromyelitis Optica Spectrum disorder: disease course and long-term visual outcome","volume":"36","author":"Brody","year":"2016","journal-title":"J. Neuroophthalmol."},{"key":"10.1016\/j.jneuroim.2021.577761_bb0045","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.msard.2017.07.014","article-title":"Patient perspectives on neuromyelitis optica spectrum disorders: data from the PatientsLikeMe online community","volume":"17","author":"Eaneff","year":"2017","journal-title":"Mult Scler Relat Disord."},{"key":"10.1016\/j.jneuroim.2021.577761_bb0050","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7861\/clinmedicine.19-2-169","article-title":"Neuromyelitis optica spectrum disorders","volume":"19","author":"Huda","year":"2019","journal-title":"Clin Med (Lond)."},{"key":"10.1016\/j.jneuroim.2021.577761_bb0055","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1742-2094-9-14","article-title":"Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients","volume":"9","author":"Jarius","year":"2012","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jneuroim.2021.577761_bb0060","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3341\/kjo.2018.0050","article-title":"Association of optic neuritis with neuromyelitis optica spectrum disorder and multiple sclerosis in Korea","volume":"33","author":"Kim","year":"2019","journal-title":"Korean J. Ophthalmol."},{"key":"10.1016\/j.jneuroim.2021.577761_bb0065","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain."},{"key":"10.1016\/j.jneuroim.2021.577761_bb0070","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s13311-015-0400-8","article-title":"Present and future therapies in neuromyelitis optica spectrum disorders","volume":"13","author":"Kleiter","year":"2016","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.jneuroim.2021.577761_bb0075","doi-asserted-by":"crossref","first-page":"101868","DOI":"10.1016\/j.msard.2019.101868","article-title":"Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder","volume":"38","author":"Kunchok","year":"2020","journal-title":"Mult Scler Relat Disord."},{"key":"10.1016\/j.jneuroim.2021.577761_bb0080","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2021.577761_bb0085","doi-asserted-by":"crossref","first-page":"129","DOI":"10.7224\/1537-2073.2017-076","article-title":"Assessment of patients with Neuromyelitis Optica spectrum disorder using the EQ-5D","volume":"21","author":"Mealy","year":"2019","journal-title":"Int J MS Care."},{"key":"10.1016\/j.jneuroim.2021.577761_bb0090","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10384-018-0602-9","article-title":"Short-term effect of additional apheresis on visual acuity changes in patients with steroid-resistant optic neuritis in neuromyelitis optica spectrum disorders","volume":"62","author":"Mori","year":"2018","journal-title":"Jpn. J. Ophthalmol."},{"key":"10.1016\/j.jneuroim.2021.577761_bb0095","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.3109\/09638288.2013.833301","article-title":"Life on hold: the experience of living with neuromyelitis optica","volume":"36","author":"Mutch","year":"2014","journal-title":"Disabil. Rehabil."},{"key":"10.1016\/j.jneuroim.2021.577761_bb0100","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1001\/archneurol.2012.768","article-title":"Association of neuromyelitis optica with severe and intractable pain","volume":"69","author":"Qian","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577761_bb0105","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000572","article-title":"Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?","volume":"6","author":"Stiebel-Kalish","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"10.1016\/j.jneuroim.2021.577761_bb0110","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1212\/WNL.0000000000001520","article-title":"Challenges and opportunities in designing clinical trials for neuromyelitis optica","volume":"84","author":"Weinshenker","year":"2015","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2021.577761_bb0115","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic\u2019s syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology."},{"key":"10.1016\/j.jneuroim.2021.577761_bb0120","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/ana.26049","article-title":"Long-term safety and efficacy of Eculizumab in Aquaporin-4 IgG-positive NMOSD","volume":"89","author":"Wingerchuk","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577761_bb0125","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1177\/1352458514522103","article-title":"Neuropathic pain in neuromyelitis optica affects activities of daily living and quality of life","volume":"20","author":"Zhao","year":"2014","journal-title":"Mult. Scler."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572821002885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572821002885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:39:41Z","timestamp":1759048781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572821002885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":25,"alternative-id":["S0165572821002885"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577761","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical burden of relapses in aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder: A single center cohort analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577761","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"577761"}}